Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin - Gee, J; Bailey, H; Kim, K; Kolesar, J; Havighurst, T; Tutsch, K D; See, W; Cohen, M B; Street, N; LeVan, L (Prostate, 2013)